Source:http://linkedlifedata.com/resource/pubmed/id/21109678
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2011-1-21
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1473-6810
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
7-8
|
pubmed:year |
2011
|
pubmed:articleTitle |
Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors.
|
pubmed:affiliation |
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. giuseppe.derosa@unipv.it
|
pubmed:publicationType |
Journal Article,
Comment
|